Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Petróleo Brasileiro SA — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Petróleo Brasileiro SA trades at $17.28 (market cap $102.10B). The key difference: Petróleo Brasileiro SA is far larger — about 22.7× ACADIA Pharmaceuticals Inc.'s market cap, and Petróleo Brasileiro SA pays a 10.58% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PBR | |
|---|---|---|
Market Cap | $4.49B | $102.10B |
Sector | Health | Technology |
52-Week High | $28.06 | $22.03 |
52-Week Low | $20.06 | $11.54 |
Enterprise Value | $3.69B | $164.64B |
Dividend Yield | — | 10.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PBR trades at $16.26, up 0.93% with a bearish technical outlook despite strong fundamentals. The company reported $488.72B revenue and $107.58B net income for 2025, with attractive valuation metrics including a 5.18 P/E ratio and 24.94% ROE. Recent earnings showed mixed results with a Q1 2026 miss but strong beats in previous quarters. Analyst consensus remains positive with a $23.90 price target, while technical indicators show bearish momentum with key support at $16.
PBR presents a compelling value opportunity with deep discount valuation and robust cash flow generation supporting substantial dividends. However, recent earnings volatility and bearish technical signals suggest near-term pressure. The stock's 46% upside to consensus target offers significant potential, but investors should monitor execution on production growth targets and global oil price stability as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
